1. ALOX5‐5‐HETE promotes gastric cancer growth and alleviates chemotherapy toxicity via MEK/ERK activation
- Author
-
Hongyan Zhu, Peng Duan, Chuang Zhang, Jian Long, Jingjing Lin, and Jianjun Tang
- Subjects
0301 basic medicine ,MAPK/ERK pathway ,Cancer Research ,Cell Survival ,MAP Kinase Signaling System ,medicine.medical_treatment ,Antineoplastic Agents ,5‐HETE ,medicine.disease_cause ,chemotherapy ,03 medical and health sciences ,0302 clinical medicine ,Stomach Neoplasms ,Hydroxyeicosatetraenoic Acids ,Medicine ,Humans ,Hydroxyurea ,Radiology, Nuclear Medicine and imaging ,Lipoxygenase Inhibitors ,Phosphorylation ,Research Articles ,RC254-282 ,Cancer Biology ,Cell Proliferation ,Chemotherapy ,Analysis of Variance ,Arachidonate 5-Lipoxygenase ,business.industry ,gastric cancer ,Cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Zileuton ,medicine.disease ,Alox5 ,Up-Regulation ,zileuton ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Cancer cell ,Cancer research ,Disease Progression ,Signal transduction ,business ,Carcinogenesis ,MEK/ERK ,medicine.drug ,Research Article - Abstract
Background Recent studies highlight the regulatory role of arachidonate lipoxygenase5 (Alox5) and its metabolite 5‐hydroxyeicosatetraenoic acid (5‐HETE) in cancer tumorigenesis and progression. In this study, we analyzed the expression, biological function and the downstream signaling of Alox5 in gastric cancer. Methods Alox5 protein levels were measured using IHC and ELISA. Growth, migration and survival assays were performed. Phosphorylation of molecules involved in growth and survival signaling were analyzed by WB. Analysis of variance and t‐test were used for statistic analysis. Results Alox5 and 5‐HETE levels were upregulated in gastric cancer patients. ALOX5 overexpression or 5‐HETE addition activates gastric cancer cells and reduces chemotherapy’s efficacy. In contrast, ALOX5 inhibition via genetic and pharmacological approaches suppresses gastric cancer cells and enhances chemotherapy’s efficacy. In addition, Alox5 inhibition led to suppression of ERK‐mediated signaling pathways whereas ALOX5‐5‐HETE activates ERK‐mediated signaling in gastric cancer cells. Conclusions Our work demonstrates the critical role of ALOX5‐5‐HETE in gastric cancer and provides pre‐clinical evidence to initialize clinical trial using zileuton in combination with chemotherapy for treating gastric cancer., Our work demonstrates that the ALOX5‐5‐HETE axis promotes gastric cancer growth and alleviates chemotherapy toxicity via MEK/ERK activation and provides pre‐clinical evidence to initialize clinical trials using zileuton in combination with chemotherapy for the treatment of gastric cancer.
- Published
- 2021